<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597412</url>
  </required_header>
  <id_info>
    <org_study_id>YMC038</org_study_id>
    <nct_id>NCT03597412</nct_id>
  </id_info>
  <brief_title>Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM</brief_title>
  <acronym>MIRA</acronym>
  <official_title>Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Type 2 Diabetes Mellitus (DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and aafety of rosuvastatin/ezetimibe combination&#xD;
      therapy vs. rosuvastatin monotherapy in atherosclerotic cardiovascular disease patients with&#xD;
      type 2 diabetes mellitus&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Actual">August 12, 2020</completion_date>
  <primary_completion_date type="Actual">August 12, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to week 24 in LDL-C level</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 in LDL-C level</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in high-sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in Apolipoprotein A1, Apolipoprotein B, Apolipoprotein B48, and Apolipoprotein B/Apolipoprotein A1</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 and week 24 in homeostasis model assessment for insulin resistance (HOMA-IR)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving LDL-C &lt; 70mg/dL</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving LDL-C &lt; 55mg/dL</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of MACCE (Major Adverse Cardiovascular and Cerebrovascular Event)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Rosuvamibe Tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monorova Tab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 20mg qd for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvamibe</intervention_name>
    <description>Rosuvastatin 10mg/Ezetimibe 10mg</description>
    <arm_group_label>Rosuvamibe Tab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monorova</intervention_name>
    <description>Rosuvastatin 20mg</description>
    <arm_group_label>Monorova Tab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 19 and above&#xD;
&#xD;
          2. Patient with type 2 diabetes taking oral diabetes medication for at least 3 months&#xD;
&#xD;
          3. Patient diagnosed with ASCVD&#xD;
&#xD;
               -  Myocardial Infarction (MI)&#xD;
&#xD;
               -  Acute coronary syndrome (ACS)&#xD;
&#xD;
               -  History of Coronary revascularization(Percutaneous Coronary Intervention, PCI)&#xD;
&#xD;
               -  History of Coronary artery bypass graft surgery (CABG) or other arterial&#xD;
                  revascularization procedures&#xD;
&#xD;
               -  Stroke or Transient ischemic attack (TIA)&#xD;
&#xD;
               -  Peripheral Arterial Disease (PAD)&#xD;
&#xD;
               -  Stable Angina&#xD;
&#xD;
          4. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes&#xD;
&#xD;
          2. HbA1c &gt; 8.5% at screening&#xD;
&#xD;
          3. Fasting triglyceride ≥ 400 mg/dL at screening&#xD;
&#xD;
          4. History of muscular disease or rhabdomyolysis due to use of statin&#xD;
&#xD;
          5. Hypersensitive to rosuvastatin or ezetemibe&#xD;
&#xD;
          6. Contraindications stated in the SPC of rosuvastatin or rosuvastatin/ezetimibe&#xD;
             including the following:&#xD;
&#xD;
             ① Severe renal disease (CrCL &lt; 30mL/min: Cockcroft-gault formula or estimated GFR&#xD;
             (MDRD) &lt; 30mL/min/1.73m2)&#xD;
&#xD;
             ② ALT, AST &gt; 3x ULN or history of active liver disease&#xD;
&#xD;
             ③ CPK &gt; 3x ULN&#xD;
&#xD;
          7. Those participating in clinical trials of other drugs&#xD;
&#xD;
          8. Other than the above who is deemed to be ineligible to participate in the trial by&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

